- Home
- ECF vs CLLS Comparison
ECF vs CLLS Comparison
Compare ECF & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECF
- CLLS
- Stock Information
- Founded
- ECF 1986
- CLLS 1999
- Country
- ECF United States
- CLLS France
- Employees
- ECF N/A
- CLLS N/A
- Industry
- ECF Finance/Investors Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ECF Finance
- CLLS Health Care
- Exchange
- ECF Nasdaq
- CLLS Nasdaq
- Market Cap
- ECF 144.8M
- CLLS 143.4M
- IPO Year
- ECF N/A
- CLLS 2007
- Fundamental
- Price
- ECF $10.56
- CLLS $2.51
- Analyst Decision
- ECF
- CLLS Buy
- Analyst Count
- ECF 0
- CLLS 1
- Target Price
- ECF N/A
- CLLS $4.00
- AVG Volume (30 Days)
- ECF 57.7K
- CLLS 285.0K
- Earning Date
- ECF 01-01-0001
- CLLS 08-04-2025
- Dividend Yield
- ECF 6.42%
- CLLS N/A
- EPS Growth
- ECF N/A
- CLLS N/A
- EPS
- ECF 0.46
- CLLS N/A
- Revenue
- ECF N/A
- CLLS $54,747,000.00
- Revenue This Year
- ECF N/A
- CLLS N/A
- Revenue Next Year
- ECF N/A
- CLLS $4.90
- P/E Ratio
- ECF $17.61
- CLLS N/A
- Revenue Growth
- ECF N/A
- CLLS 351.26
- 52 Week Low
- ECF $7.02
- CLLS $1.10
- 52 Week High
- ECF $8.91
- CLLS $3.10
- Technical
- Relative Strength Index (RSI)
- ECF 63.93
- CLLS 62.22
- Support Level
- ECF $10.50
- CLLS $2.00
- Resistance Level
- ECF $10.65
- CLLS $3.10
- Average True Range (ATR)
- ECF 0.09
- CLLS 0.29
- MACD
- ECF -0.01
- CLLS 0.07
- Stochastic Oscillator
- ECF 58.82
- CLLS 60.14
About ECF Ellsworth Growth and Income Fund Ltd.
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.